Wilson Sonsini Goodrich & Rosati represented Halia Therapeutics in the transaction. Halia Therapeutics announced it raised $30 million in Series C financing round led by Todd Pedersen, with continued...
Halia Therapeutics’ $30 Milliion Series C Financing Round
Unilever’s Acquisition of K18
Wilson Sonsini Goodrich & Rosati is advising K18 on the transaction. Unilever announced it signed an agreement to acquire premium biotech haircare brand K18. Founded in 2020...
Vivodyne’s $38 Million Seed Financing Round
Wilson Sonsini Goodrich & Rosati advised Khosla Ventures on the transaction. Vivodyne announced the close of $38 million in total seed financing, led by Khosla Ventures, with...
DermBiont’s $35.2 Million Series B Financing Round
Wilson Sonsini Goodrich & Rosati provided IP and corporate counsel to DermBiont in the transaction. DermBiont announced its $35.2 million Series B financing. The financing was led...
Boundless Bio’s $100 Million Series C Financing
Wilson Sonsini Goodrich & Rosati advised Boundless Bio on IP matters related to the transaction. Boundless Bio, a clinical-stage, next-generation precision oncology company developing innovative therapeutics...
Prometheus Biosciences’ $500 Million Shares Offering
Wilson Sonsini and Latham & Watkins advised Prometheus Biosciences on the deal, while Davis Polk & Wardwell advised the representatives of the several underwriters. Prometheus Biosciences,...
Prometheus Biosciences’ $190 Million IPO
Wilson Sonsini Goodrich & Rosati and Latham & Watkins advised Prometheus Biosciences on the deal, while Davis Polk advised the representatives of the underwriters. Prometheus Biosciences,...
Janux Therapeutics’ $56 Million Series A Financing
Wilson Sonsini Goodrich & Rosati advised Janux Therapeutics on the deal. Janux Therapeutics, a developer of safe, effective novel immunotherapies using its proprietary Tumor Activated T...